论文部分内容阅读
以往的实验证实增殖性玻璃体视网膜病变（ＰＶＲ）炎症期给以道诺霉素效果有限。我们在巨噬细胞注入兔玻璃体后６天再注入道诺霉素５μｇ，采用３Ｈ－胸腺嘧啶放射自显影观察了眼内细胞增生率，并与去炎松和两药联合的作用进行了比较。在２８天时，道诺霉素组、去炎松组、联合用药组及对照组视网膜脱离率分别为３３．３％、１６，１％、８．３％和８３．３％（Ｐ＜０．０１）。放射自显影观察，道诺霉素使１、２周的标记细胞数明显减少（与对照组比分别为１８．８±３．２对３５．７±３．４；５２．１±８，０对８１．３±１４．６．Ｐ＜０．０１）：而去大松及联合用药使炎细胞和标记细胞都明显减少。由此证实在ＰＶＲ炎症期应用去炎松、细胞增生期应用道诺霉素或联合用药可防治牵拉性视网膜脱离。
Previous experiments confirmed that proliferative vitreoretinopathy (PVR) inflammation period to give daunomycin limited. We injected daunorubicin 5 μg 6 days after the macrophages were infused into the rabbit’s vitreous and the intraocular cell proliferation was observed by 3H-thymidine autoradiography and compared with the combination of triamcinolone and the two drugs. The retinal detachment rates in daunorubicin group, triamcinolone acetonide group, combination group and control group were 33.3%, 16.1%, 8.3% and 83.3% respectively at 28 days (P <0. 01). Autoradiography showed that daunorubicin significantly decreased the number of labeled cells at 1 and 2 weeks (compared with the control group, respectively, 18.8 ± 3.2 vs 35.7 ± 3.4; 52.1 ± 8 and 0 To 81.3 ± 14.6.P <0.01). However, the decrease of both inflammatory cells and labeled cells was observed when the drug was given to the rats and the combination therapy. Thus confirmed in the PVR inflammation phase of the application of triamcinolone, cell proliferation of daunorubicin or combination therapy can prevent traction retinal detachment.